Literature DB >> 11134384

Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented.

P Chen1, G Ratcliff, S H Belle, J A Cauley, S T DeKosky, M Ganguli.   

Abstract

OBJECTIVE: To identify the most accurate cognitive measures in discriminating between individuals with presymptomatic AD and individuals who remained nondemented.
METHODS: During a 10-year prospective community study, 120 nondemented subjects completed a battery of standard cognitive tests and clinically manifested AD 1.5 years later. Performance on each of 16 cognitive tests was compared between these 120 presymptomatic cases and 483 controls who remained nondemented over the 10-year follow-up period. The area under the receiver operating characteristic (AUC) curve for each test was used to measure its accuracy of discrimination between cases and controls.
RESULTS: Among the 16 neuropsychological tests, Word List Delayed Recall discriminated best between cases and controls (AUC = 0.806), followed by the Word List 3rd Learning Trial (0.787), Word List 1st Learning Trial (0.774), and Trail-making Test B (0.773), compared to the Mini-Mental State Examination (MMSE) (0.726). Both Word List Delayed Recall and Word List 3rd Learning Trial were significantly more accurate than the MMSE. The combination of Word List Delayed Recall and Trail-making Test B comprised the optimal set of cognitive measures, with the highest AUC (0.852).
CONCLUSION: Measures of delayed recall and executive functions were the best discriminators between those who would manifest AD 1.5 years later and those who would remain nondemented. These findings are relevant for the early detection of AD and, therefore, for prevention and early intervention trials. Executive dysfunction may be a subtle manifestation of incipient AD, along with memory dysfunction.

Entities:  

Mesh:

Year:  2000        PMID: 11134384     DOI: 10.1212/wnl.55.12.1847

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  78 in total

Review 1.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

3.  Premorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotype.

Authors:  J Cervilla; M Prince; S Joels; S Lovestone; A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

4.  Association between white matter microstructure, executive functions, and processing speed in older adults: the impact of vascular health.

Authors:  Heidi I L Jacobs; Elizabeth C Leritz; Victoria J Williams; Martin P J Van Boxtel; Wim van der Elst; Jelle Jolles; Frans R J Verhey; Regina E McGlinchey; William P Milberg; David H Salat
Journal:  Hum Brain Mapp       Date:  2011-09-23       Impact factor: 5.038

5.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

6.  Memory-provoked rCBF-SPECT as a diagnostic tool in Alzheimer's disease?

Authors:  Torbjörn Sundström; Eva Elgh; Anne Larsson; Birgitta Näsman; Lars Nyberg; Katrine A Riklund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

Review 7.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

Review 8.  Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review.

Authors:  Michal Harciarek; Krzysztof Jodzio
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

9.  Self-administered screening for mild cognitive impairment: initial validation of a computerized test battery.

Authors:  Jane B Tornatore; Emory Hill; Jo Anne Laboff; Mary E McGann
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

10.  Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus.

Authors:  Stefan J Teipel; Wilhelm Flatz; Nibal Ackl; Michel Grothe; Ingo Kilimann; Arun L W Bokde; Lea Grinberg; Edson Amaro; Vanja Kljajevic; Eduardo Alho; Christina Knels; Anne Ebert; Helmut Heinsen; Adrian Danek
Journal:  Psychiatry Res       Date:  2013-12-06       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.